EMA taking second hard look at Ariad's Iclusig

The European Medicines Agency (EMA) has decided to look again at the clotting risks of Ariad Pharmaceuticals' ($ARIA) troubled cancer drug Iclusig. The FDA recently had the company pull the drug. Shares of the company fell 10%. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.